Hospasol

Hospasol is an intravenous preparation containing sodium hydrogen carbonate as its sole active ingredient. The product is supplied in a sterile solution for parenteral administration, with the specific concentration not disclosed in the public label. Originating from the European Union market, Hospasol is classified as a pharmaceutical agent used to modify systemic acid‑base balance when rapid correction is required in clinical settings under medical supervision.

Hospasol is employed in medical practice where rapid adjustment of blood pH is needed.

- Correction of metabolic acidosis during surgery or critical care. - Management of severe electrolyte disturbances associated with acid‑base imbalance. - Adjunct in cardiopulmonary bypass circuits to maintain appropriate pH. - Supportive therapy for patients receiving large volumes of chloride‑rich fluids. - Use in renal replacement therapies to buffer systemic acidity. - Preparation of buffered solutions for laboratory or diagnostic use in hospital settings.

Adverse reactions to intravenous sodium hydrogen carbonate are generally related to its alkalinizing effect and electrolyte load.

Common: - Transient facial flushing or a sensation of warmth during the infusion. - Mild nausea, occasional vomiting, or abdominal discomfort. - Temporary rise in serum sodium concentration without clinical sequelae. - Mild metabolic alkalosis reflected by a modest increase in arterial pH. - Local irritation at the infusion site.

Serious: - Severe metabolic alkalosis that may precipitate hypokalemia and muscle weakness. - Cardiac arrhythmias, including premature beats or tachyarrhythmias, linked to electrolyte disturbances. - Pulmonary edema resulting from rapid intravascular volume expansion. - Hypernatremia presenting with neurologic signs such as confusion, lethargy, or seizures. - Seizures directly attributable to extreme alkalosis and electrolyte imbalance.

When using Hospasol, clinicians should observe several precautionary measures to minimize risk and ensure appropriate patient selection.

- Verify baseline arterial blood gas and electrolyte values before administration. - Avoid use in patients with known hypersensitivity to sodium bicarbonate or related compounds. - Use caution in individuals with congestive heart failure or fluid overload risk. - Adjust or withhold therapy in patients with severe renal impairment or uncontrolled hypertension. - Monitor serum sodium, potassium, and pH frequently during and after infusion. - Limit infusion rate to recommended clinical guidelines to prevent rapid pH shifts. - Ensure adequate ventilation to facilitate carbon dioxide elimination.

Intravenous sodium hydrogen carbonate can interact with other medications or clinical conditions, requiring attention to avoid adverse outcomes.

Avoid: - Concomitant use of strong acids or acidifying agents that counteract alkalinization. - High-dose loop diuretics that may exacerbate electrolyte disturbances. - Medications that prolong the QT interval when severe alkalosis is present.

Use with caution: - Calcium channel blockers, as rapid pH changes can affect calcium binding. - Certain antibiotics (e.g., aminoglycosides) where altered pH may influence renal clearance. - Blood products, because bicarbonate may affect coagulation parameters. - Vasopressors, since volume shifts can modify hemodynamic response.